Pfizer's Pristiq shows efficacy as hot flash treatment in clinical trial
5 May 2011 00:00 in Pharmaceutical Company Product News
Pfizer has published clinical trial data that supports the effectiveness of its drug Pristiq for the treatment of hot flashes in postmenopausal women.
Results from a phase III efficacy sub-study of the extended release tablets have been presented by Pfizer at the annual clinical meeting of the American College of Obstetricians and Gynecologists.
The data shows that the drug significantly reduced the number and severity of moderate-to-severe hot flashes among the 365-patient study group compared to placebo, meeting all four co-primary endpoints in the process.
Pfizer is hoping that this data can support its regulatory application for the drug - which is currently approved as an antidepressant - to be ratified in this new specification.
Dr Steven Romano, senior vice-president and head of the medicines development group for Pfizer's primary care business unit, said: "Pfizer is committed to women's health and understands the impact that hot flashes and night sweats related to menopause can have on a woman's life."
According to Pfizer's new financial report published this week, the company generated revenues in the first quarter of 2011 that were consistent with the corresponding period of last year.
Other news stories from 05/05/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency